To provide for certain causes of action relating to delays of generic drugs and biosimilar biological products.

IN THE SENATE OF THE UNITED STATES

Mr. Leahy (for himself, Mr. Grassley, Ms. Klobuchar, and Mr. Lee) introduced the following bill; which was read twice and referred to the Committee on

A BILL

To provide for certain causes of action relating to delays of generic drugs and biosimilar biological products.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Creating and Restoring Equal Access to Equivalent Samples Act of 2016” or the “CREATEES Act of 2016”.

SEC. 2. FINDINGS.

Congress finds the following:

(1) It is the policy of the United States to promote competition in the market for drugs and bio-
logical products by facilitating the timely entry of
low-cost generic and biosimilar versions of those
drugs and biological products.

(2) Since their enactment in 1984 and 2010 re-
spectively, the Drug Price Competition and Patent
Term Restoration Act of 1984 (Public Law 98–417;
98 Stat. 1585) and the Biologics Price Competition
and Innovation Act of 2009 (Subtitle A of title VII
of Public Law 111–148; 124 Stat. 804), have pro-
vided pathways for making lower-cost versions of
previously approved drugs and previously licensed bi-
ological products available to the people of the
United States in a timely manner, thereby lowering
overall prescription drug costs for patients and tax-
payers by billions of dollars each year.

(3) In order for these pathways to function as
intended, developers of generic drugs and biosimilar
biological products (referred to in this section as
“generic product developers”) must be able to obtain
quantities of the reference listed drug or biological
product with which the generic drug or biosimilar bi-
ological product is intended to compete (referred to
in this section as a “covered product”) for purposes
of supporting an application for approval by the
Food and Drug Administration, including for testing to show that—

(A) a prospective generic drug is bioequivalent to the covered product in accordance with subsection (j) of section 505 of the Federal, Food, Drug, and Cosmetic Act (21 U.S.C. 355), or meets the requirements for approval of an application submitted under subsection (b)(2) of that section; or

(B) a prospective biosimilar biological product is biosimilar to or interchangeable with its reference biological product under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), as applicable.

(4) For drugs and biological products that are subject to a risk evaluation and mitigation strategy, another essential component in the creation of low-cost generic and biosimilar versions of covered products is the ability of generic product developers to join the manufacturer of the covered product (referred to in this section as the “license holder”) in a single, shared system of elements to assure safe use and supporting agreements, or secure a variance therefrom, as required by section 505–1 of the Fed-

(5) Contrary to the policy of the United States to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, certain license holders are preventing generic product developers from obtaining quantities of the covered product necessary for the generic product developer to support an application for approval by the Food and Drug Administration, including testing to show bioequivalence, biosimilarity, or interchangeability to the covered product, in some instances based on the justification that the covered product is subject to a risk evaluation and mitigation strategy with elements to assure safe use under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1).

(6) The Director of the Center for Drug Evaluation and Research at the Food and Drug Administration has testified that some manufacturers of covered products have used REMS and distribution restrictions adopted by the manufacturer on their own behalf as reasons to not sell quantities of a covered product to generic product developers, causing
barriers and delays in getting generic products on
the market. The Food and Drug Administration has
reported receiving significant numbers of inquiries
from generic product developers who were unable to
obtain samples of covered products to conduct nec-
essary testing and otherwise meet requirements for
approval of generic drugs.

(7) The Chairwoman of the Federal Trade
Commission has testified that the Federal Trade
Commission continues to be very concerned about
potential abuses by manufacturers of brand drugs of
REMS or other closed distribution systems to im-
pede generic competition.

(8) Also contrary to the policy of the United
States to promote competition in the market for
drugs and biological products by facilitating the
timely entry of lower-cost generic and biosimilar
versions of those drugs and biological products, cer-
tain license holders are impeding the prompt nego-
tiation and development on commercially reasonable
terms of a single, shared system of elements to as-
sure safe use, which may be necessary for the ge-
neric product developer to gain approval for its drug
or licensing for its biological product.
While the antitrust laws may address the refusal by some license holders to provide quantities of a covered product to a generic product developer, a more tailored legal pathway would help ensure that generic product developers can obtain necessary quantities of a covered product in a timely way for purposes of developing a generic drug or biosimilar biological product, facilitating competition in the marketplace for drugs and biological products.

While the antitrust laws may address actions by license holders who impede the prompt negotiation and development on commercially reasonable terms of a single, shared system of elements to assure safe use, a more tailored legal pathway would help ensure that license holders negotiate such agreements in good faith and in a timely manner, facilitating competition in the marketplace for drugs and biological products.

SEC. 3. ACTIONS FOR DELAYS OF GENERIC DRUGS AND BIOSIMILAR BIOLOGICAL PRODUCTS.

(a) DEFINITIONS.—In this section—

(1) the term “covered product”—

(A) means—

(i) any drug approved under subsection (b) or (j) of section 505 of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 355) or biological product licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (42 U.S.C. 262);

(ii) any combination of a drug or biological product described in clause (i); or

(iii) when reasonably necessary to demonstrate sameness, biosimilarity, or interchangeability for purposes of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), or section 351 of the Public Health Service Act (42 U.S.C. 262), as applicable, any product, including any device, that is marketed or intended for use with such drug or biological product; and

(B) does not include any drug or biological product that the Secretary has determined to be currently in shortage and that appears on the drug shortage list in effect under section 506E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356e), unless the shortage will not be promptly resolved—
(i) as demonstrated by the fact that the drug or biological product has been in shortage for more than 6 months; or
(ii) as otherwise determined by the Secretary;

(2) the term “device” has the meaning given the term in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321);

(3) the term “eligible product developer” means a person that seeks to develop a product for approval pursuant to an application for approval under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or for licensing pursuant to an application under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k));

(4) the term “license holder” means the holder of an application approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or the holder of a license under subsection (a) or (k) of section 351 of the Public Health Service Act (42 U.S.C. 262) for a covered product;

(5) the term “REMS” means a risk evaluation and mitigation strategy under section 505–1 of the
(6) the term “REMS with ETASU” means a REMS that contains elements to assure safe use under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1);

(7) the term “Secretary” means the Secretary of Health and Human Services;

(8) the term “single, shared system of elements to assure safe use” means a single, shared system of elements to assure safe use under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1); and

(9) the term “sufficient quantities” means an amount of a covered product that allows the eligible product developer to—

(A) conduct testing to support an application—

(i) for approval under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or

(ii) for licensing under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)); and
(B) fulfill any regulatory requirements relating to such an application for approval or licensing.

(b) Civil Actions.—

(1) Failure to provide sufficient quantities of a covered product.—

(A) In general.—An eligible product developer may bring a civil action against the license holder for a covered product seeking relief under this paragraph in an appropriate district court of the United States alleging that the license holder has declined to provide sufficient quantities of the covered product to the eligible product developer on commercially reasonable, market-based terms.

(B) Elements.—

(i) In general.—To prevail in a civil action brought under subparagraph (A), an eligible product developer shall prove, by a preponderance of the evidence—

(I) that—

(aa) the covered product is not subject to a REMS with ETASU; or
(bb) if the covered product is subject to a REMS with ETASU—

(AA) the eligible product developer has obtained a covered product authorization from the Secretary in accordance with clause (ii); and

(BB) the eligible product developer has provided a copy of the covered product authorization to the license holder;

(II) that, as of the date on which the civil action is filed, the product developer has not obtained sufficient quantities of the covered product on commercially reasonable, market-based terms;

(III) that the eligible product developer has requested to purchase sufficient quantities of the covered product from the license holder; and
(IV) that the license holder has not delivered to the eligible product developer sufficient quantities of the covered product on commercially rea-
sonable, market-based terms—

(aa) for a covered product that is not subject to a REMS with ETASU, by the date that is 31 days after the date on which the license holder received the re-
quest for the covered product; and

(bb) for a covered product that is subject to a REMS with ETASU, by 31 days after the later of—

(AA) the date on which the license holder received the request for the covered product; or

(BB) the date on which the license holder received a copy of the covered product authorization issued by the
Secretary in accordance with clause (ii).

(ii) AUTHORIZATION FOR COVERED PRODUCT SUBJECT TO A REMS WITH ETASU.—

(I) REQUEST.—An eligible product developer may submit to the Secretary a written request for the eligible product developer to be authorized to obtain sufficient quantities of an individual covered product subject to a REMS with ETASU.

(II) AUTHORIZATION.—Not later than 90 days after the date on which a request under subclause (I) is received, the Secretary shall, by written notice, authorize the eligible product developer to obtain sufficient quantities of an individual covered product subject to a REMS with ETASU for purposes of—

(aa) development and testing that does not involve human clinical trials, if the eligible product developer has agreed to com-
ply with any conditions the Secretary determines necessary; or

(bb) development and testing that involves human clinical trials, if the eligible product developer has—

(AA) submitted protocols, informed consent documents, and informational materials for testing that include protections that provide safety protections comparable to those provided by the REMS for the covered product; or

(BB) otherwise satisfied the Secretary that such protections will be provided.

(III) NOTICE.—A covered product authorization issued under this clause shall state that the provision of the covered product by the license holder under the terms of the authorization will not be a violation of the REMS for the covered product.
(C) AFFIRMATIVE DEFENSE.—In a civil action brought under subparagraph (A), it shall be an affirmative defense, on which the defendant has the burden of persuasion by a preponderance of the evidence—

(i) that, on the date on which the eligible product developer requested to purchase sufficient quantities of the covered product from the license holder—

(I) neither the license holder nor any of its agents, wholesalers, or distributors was engaged in the manufacturing or commercial marketing of the covered product; and

(II) neither the license holder nor any of its agents, wholesalers, or distributors otherwise had access to inventory of the covered product to supply to the eligible product developer on commercially reasonable, market-based terms; or

(ii) that—

(I) the license holder sells the covered product through agents, distributors, or wholesalers;
(II) the license holder has placed no restrictions, explicit or implicit, on its agents, distributors, or wholesalers to sell covered products to eligible product developers; and

(III) the covered product can be purchased by the eligible product developer in sufficient quantities on commercially reasonable, market-based terms from the agents, distributors, or wholesalers of the license holder.

(D) REMEDIES.—

(i) IN GENERAL.—If an eligible product developer prevails in a civil action brought under subparagraph (A), the court shall—

(I) order the license holder to provide to the eligible product developer without delay sufficient quantities of the covered product on commercially reasonable, market-based terms;
(II) award to the eligible product developer reasonable attorney fees and costs of the civil action; and

(III) award to the eligible product developer a monetary amount sufficient to deter the license holder from failing to provide other eligible product developers with sufficient quantities of a covered product on commercially reasonable, market-based terms, if the court finds, by a preponderance of the evidence—

(aa) that the license holder delayed providing sufficient quantities of the covered product to the eligible product developer without a legitimate business justification; or

(bb) that the license holder failed to comply with an order issued under subclause (I).

(ii) MAXIMUM MONETARY AMOUNT.—

A monetary amount awarded under clause (i)(III) shall not be greater than the rev-
enue that the license holder earned on the
covered product during the period—

(I) beginning on—

(aa) for a covered product
that is not subject to a REMS
with ETASU, the date that is 31
days after the date on which the
license holder received the re-
quest; or

(bb) for a covered product
that is subject to a REMS with
ETASU, the date that is 31 days
after the later of—

(AA) the date on which
the license holder received
the request; or

(BB) the date on which
the license holder received a
copy of the covered product
authorization issued by the
Secretary in accordance with
subparagraph (B)(ii); and

(II) ending on the date on which
the eligible product developer received
sufficient quantities of the covered product.

(iii) AVOIDANCE OF DELAY.—The court may issue an order under clause (i)(I) before conducting further proceedings that may be necessary to determine whether the eligible product developer is entitled to an award under subclause (II) or (III) of clause (i), or the amount of any such award.

(2) FAILURE TO REACH AGREEMENT ON SHARED SYSTEM.—

(A) IN GENERAL.—An eligible product developer may bring a civil action against the license holder for a covered product seeking relief under this paragraph in an appropriate district court of the United States alleging the license holder—

(i) failed to reach agreement with respect to a single, shared system of elements to assure safe use with respect to the covered product; or

(ii) refused to allow the eligible product developer to join a previously approved
system of elements to assure safe use with respect to that product.

(B) ELEMENTS.—To prevail in a civil action brought under subparagraph (A), an eligible product developer shall prove, by a preponderance of the evidence, that—

(i) the eligible product developer has sought approval of an application for approval under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or has sought a license for a biological product under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) referencing a covered product subject to a REMS with ETASU;

(ii) the covered product is subject to a REMS with ETASU that requires a single, shared system of elements to assure safe use with respect to the covered product;

(iii) at least 120 days have elapsed since the developer first initiated an attempt to reach an agreement with the license holder that would allow the product
developer to participate in a single, shared system of elements to assure safe use;

(iv) the license holder and eligible product developer have not reached an agreement that would allow the eligible product developer to participate in a single, shared system of elements to assure safe use on commercially reasonable terms; and

(v) the Secretary has not waived the requirement for the covered product to be part of such a single, shared system.

(C) REMEDIES.—

(i) IN GENERAL.—If an eligible product developer prevails in a civil action brought under subparagraph (A), the court shall—

(I) order the license holder to—

(aa) with the approval of the Secretary, enter into a single, shared system of elements to assure safe use with the eligible product developer on commercially reasonable terms;

(bb) with the approval of the Secretary, allow the eligible prod-
uct developer to join a previously approved system of elements to assure safe use with respect to the covered product on commercially reasonable terms; or

(cc) demonstrate that the Secretary has waived the requirement for the covered product to be part of a single, shared system of elements to assure safe use;

(II) award to the eligible product developer reasonable attorney fees and costs of the civil action; and

(III) award to the eligible product developer a monetary amount sufficient to deter the license holder from failing to reach agreements that would allow other eligible product developers to participate in a single, shared system of elements to assure safe use on commercially reasonable terms if the court finds, by a preponderance of the evidence——
(aa) that the license holder, without a legitimate business justification, delayed—

(AA) the entry of the eligible product developer into a single, shared system of elements to assure safe use with respect to the covered product; or

(BB) the securing of a waiver of the requirement of a single, shared system of elements to assure safe use with respect to the covered product; or

(bb) that the license holder failed to comply with an order issued under subclause (I).

(ii) MAXIMUM MONETARY AMOUNT.—

A monetary amount awarded under clause (i)(III) shall not be greater than the revenue that the license holder earned on the covered product during the period—

(I) beginning on the date that is 121 days after the date on which the
product developer first initiated an attempt to reach an agreement with the license holder that would allow the product developer to participate in a single, shared system of elements to assure safe use with respect to the covered product; and

(II) ending on the date on which the eligible product developer and license holder reached an agreement that would allow the product developer to participate in a single, shared system of elements to assure safe use with respect to the covered product.

(iii) AVOIDANCE OF DELAY.—The court may issue an order under clause (i)(I) before conducting further proceedings that may be necessary to determine whether the eligible product developer is entitled to an award under subclause (II) or (III) of clause (i), or the amount of any such award.

(e) LIMITATION OF LIABILITY.—A license holder shall not be liable for any claim arising out of the failure of an eligible product developer to follow adequate safe-
guards to assure safe use of the covered product during
development or testing activities described in this section,
including transportation, handling, use, or disposal of the
covered product by the eligible product developer.

(d) RULE OF CONSTRUCTION.—

(1) DEFINITION.—In this subsection, the term
“antitrust laws”—

(A) has the meaning given the term in
subsection (a) of the first section of the Clayton
Act (15 U.S.C. 12); and

(B) includes section 5 of the Federal
Trade Commission Act (15 U.S.C. 45) to the
extent that such section applies to unfair meth-
ods of competition.

(2) ANTITRUST LAWS.—Nothing in this section
shall be construed to limit the operation of any pro-
vision of the antitrust laws.